Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032784 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
A Phase 4 study, sponsored by AdventHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT02032784 is a Phase 4 study that was terminated before completion, run by AdventHealth. The registered enrollment target is 33 participants.
The verdict
NCT02032784, a Phase 4 study, was terminated before completion, sponsored by AdventHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
Interventions
- DRUG octreotide
- OTHER No Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032784
The ClinicalTrials.gov registry entry for NCT02032784 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which octreotide is the first listed.
NCT02032784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032784 about?
NCT02032784 is a clinical study titled "Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding". Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
What is the current status of trial NCT02032784?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2014-03. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT02032784?
The interventions under investigation include: octreotide (DRUG), No Octreotide (OTHER).
Who is sponsoring clinical trial NCT02032784?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.